INCLINE VILLAGE, Nev. , Aug. 18, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will issue its second quarter financial results after market today and has rescheduled its second quarter earnings call to discuss the financial results for tomorrow,
INCLINE VILLAGE, Nev. , Aug. 8, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has filed a Form 12b-25 Notification of Late Filing with the U.S. Securities and Exchange Commission (SEC) allowing for a five-day extension to file its Quarterly Report
INCLINE VILLAGE, Nev. , July 30, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that company management will participate in the Jefferies 2014 Boston Healthcare Summit next week in Boston , Massachusetts. The conference will occur on August 6, 2014 and will not be
INCLINE VILLAGE, Nev. , July 28, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2014 financial results for the period ended June 30, 2014 , on Monday, August 11, 2014 , after market close.
INCLINE VILLAGE, Nev. , June 24, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will participate in the following conferences this week. JMP Securities Healthcare Conference Wednesday, June
INCLINE VILLAGE, Nev. , June 12, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 12, 2014, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 5, 2014, the record date.
INCLINE VILLAGE, Nev. , June 10, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the second quarter ending June 30, 2014, of approximately $140 million , as compared with actual revenue of $143.6 million for the second quarter of 2013, an
INCLINE VILLAGE, Nev. , June 4, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 ( May 2015 Notes), is 165.4367 shares of common stock per $1,000 principal amount or approximately
INCLINE VILLAGE, Nev. , May 29, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference next week in New York City. The
INCLINE VILLAGE, Nev. , May 8, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia , the company's vice president and chief financial officer, will present at the Bank of America Merrill Lynch Health Care Conference next week in Las Vegas , Nevada. The
INCLINE VILLAGE, Nev. , May 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2014 financial results for the period ended March 31, 2014 , on Monday, May 12, 2014 , after market close.
INCLINE VILLAGE, Nev. , April 7, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that it has acquired $150 million of Notes due 2029 (the Notes) from Accel 300, LLC, a wholly-owned subsidiary of kaleo, Inc. (formerly known as Intelliject, Inc. ) (kaleo).
